Warm antibody autoimmune hemolytic anemia

Area of Science:

• Hematology
• Immunology
• Rare Diseases

Background:

• Autoimmune hemolytic anemia (AIHA) is a rare disorder affecting 1-3/100,000 individuals annually.
• Warm autoantibody AIHA (w-AIHA) is the most prevalent form, accounting for 70-80% of adult and 50% of pediatric cases.
• w-AIHA can be primary (idiopathic) or secondary to other conditions.

Purpose of the Study:

• To review the immunopathogenetic mechanisms of idiopathic and secondary w-AIHA.
• To discuss direct antiglobulin test-negative AIHA, its challenges, and fatal potential.
• To explore w-AIHA associated with immune dysregulation and outline management strategies and therapeutic options.

Main Methods:

• Literature review of immunopathogenetic mechanisms.
• Analysis of clinical characteristics and diagnostic challenges.
• Review of current and emerging treatment strategies.

Main Results:

• w-AIHA pathogenesis involves autoantibodies reacting with red blood cells at 37°C.
• Direct antiglobulin test-negative AIHA presents diagnostic and therapeutic difficulties, increasing fatality risk.
• Genetic immune dysregulation disorders can be associated with w-AIHA, requiring specialized management.

Conclusions:

• Understanding w-AIHA mechanisms is crucial for diagnosis and treatment.
• Addressing diagnostic delays and unique antibody characteristics is vital for improving outcomes in rare AIHA cases.
• Comprehensive management, including standard and novel therapies, is essential for this chronic autoimmune blood disorder.